Abstract:Clonal hematopoiesis (CH) describes the clonal expansion of blood cells derived from hematopoietic stem/progenitor cell (HSPC) sharing the same somatic mutations. Recent large deep sequencing studies revealed that CH somatic mutations are prevalent in peripheral blood cells of individuals without overt hematological abnormalities and become increasingly common and larger in clone size with age. While the risk of eventual progression to hematologic abnormalities or leukemia appears to be higher in individuals with CH, the parameters impacting on progression are unclear. In addition, CH confers a greater risk for cardiovascular disease (CVD) and possibly other systemic diseases. However, commonly used experimental animals such as mice do not develop CH and there is a lack of natural in vivo model organisms to investigate the mechanisms underlying CH development and malignant progression. We addressed this unmet need via the investigation of the rhesus macaque (RM) as a potential model organism for CH given the close phylogenetic relationship to humans and the associated comparable HSPC frequencies, replication times, telomere lengths and bone marrow environments. We assessed the incidence and variant allele frequency (VAF) of CH somatic mutations in 35 aged RM (median age 27) by error-corrected targeted ultra-deep sequencing of the exons from the top 56 human CH genes. We identified 7 animals (median age 30) carrying at least one somatic mutation in CH genes on this panel with a VAF between 0.5% to 11.4%. Furthermore, in one animal where longitudinal samples were available, we observed a gradual expansion of a one-base pair deletion in DNMT3A across multiple cell-lineage as a function of age. All animals showed normal complete blood counts and were without overt hematological malignancies. While we continue to expand our study cohort, data so far suggest that RM is a natural model for CH. Clonal hematopoiesis (CH) describes the clonal expansion of blood cells derived from hematopoietic stem/progenitor cell (HSPC) sharing the same somatic mutations. Recent large deep sequencing studies revealed that CH somatic mutations are prevalent in peripheral blood cells of individuals without overt hematological abnormalities and become increasingly common and larger in clone size with age. While the risk of eventual progression to hematologic abnormalities or leukemia appears to be higher in individuals with CH, the parameters impacting on progression are unclear. In addition, CH confers a greater risk for cardiovascular disease (CVD) and possibly other systemic diseases. However, commonly used experimental animals such as mice do not develop CH and there is a lack of natural in vivo model organisms to investigate the mechanisms underlying CH development and malignant progression. We addressed this unmet need via the investigation of the rhesus macaque (RM) as a potential model organism for CH given the close phylogenetic relationship to humans and the associated comparable HSPC frequencies, replication times, telomere lengths and bone marrow environments. We assessed the incidence and variant allele frequency (VAF) of CH somatic mutations in 35 aged RM (median age 27) by error-corrected targeted ultra-deep sequencing of the exons from the top 56 human CH genes. We identified 7 animals (median age 30) carrying at least one somatic mutation in CH genes on this panel with a VAF between 0.5% to 11.4%. Furthermore, in one animal where longitudinal samples were available, we observed a gradual expansion of a one-base pair deletion in DNMT3A across multiple cell-lineage as a function of age. All animals showed normal complete blood counts and were without overt hematological malignancies. While we continue to expand our study cohort, data so far suggest that RM is a natural model for CH.

Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease

Clonal Hematopoiesis and Bone Marrow Inflammation

Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction

Clonal hematopoiesis: Molecular and clinical implications

Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies

Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.

Decoding Clonal Hematopoiesis: Emerging Themes and Novel Mechanistic Insights

Clonal hematopoiesis and associated diseases: A review of recent findings

Data Driven Computational Modeling of Hematopoiesis in Myelodysplastic Syndromes Unveils Differences in Hematopoietic Stem Cell Kinetics Compared to Age-Matched Healthy Controls

Clonal hematopoiesis of indeterminate potential and cardiovascular disease: Pathogenesis, clinical presentation, and future directions

Clonal hematopoiesis and hematological malignancy

Clinical and Therapeutic Implications of Clonal Hematopoiesis

The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy

Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis

3154 – RHESUS MACAQUES AS NATURAL MODELS FOR AGE-RELATED CLONAL HEMATOPOIESIS

Mesenchymal Stromal Cell Senescence Induced by -Mutant Hematopoietic Cells is a Targetable Mechanism Driving Clonal Hematopoiesis and Initiation of Hematologic Malignancy

A Feedback Loop: Interactions Between Inflammatory Signals and Clonal Hematopoiesis in Cardiovascular Disease

Clonal haematopoiesis and dysregulation of the immune system

Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions

CHIP: a clonal odyssey of the bone marrow niche